One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Testing in a Pandemic — Improving Access, Coordination, and Prioritization
Yolanda Botti-Lodovico, M.P.P., Eric Rosenberg, M.D., and Pardis C. Sabeti, D.Phil., M.D.
doi : 10.1056/NEJMp2025173
N Engl J Med 2021; 384:197-199
Roman Catholic Diocese of Brooklyn v. Cuomo — The Supreme Court and Pandemic Controls
Wendy E. Parmet, J.D.
doi : 10.1056/NEJMp2034280
N Engl J Med 2021; 384:199-201
Incarceration and Social Death — Restoring Humanity in the Clinical Encounter
Bisan A. Salhi, M.D., Ph.D., and Anwar D. Osborne, M.D., M.P.M.
doi : 10.1056/NEJMp2023874
N Engl J Med 2021; 384:201-203
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Erica B. Esrick, M.D., Leslie E. Lehmann, M.D., Alessandra Biffi, M.D., Ph.D., Maureen Achebe, M.D., Christian Brendel, Ph.D., Marioara F. Ciuculescu, M.D., Heather Daley, B.S., Brenda MacKinnon, B.S.N., R.N., Emily Morris, M.P.H., Amy Federico, C.P.N.P., Daniela Abriss, Ph.D., Kari Boardman, B.S.,
doi : 10.1056/NEJMoa2029392
N Engl J Med 2021; 384:205-215
Sickle cell disease is characterized by hemolytic anemia, pain, and progressive organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising ?- and ?-globins may ameliorate these manifestations by mitigating sickle hemoglobin polymerization and erythrocyte sickling. BCL11A is a repressor of ?-globin expression and HbF production in adult erythrocytes. Its down-regulation is a promising therapeutic strategy for induction of HbF.
Polypill with or without Aspirin in Persons without Cardiovascular Disease
Salim Yusuf, D.Phil., Philip Joseph, M.D., Antonio Dans, M.D., Peggy Gao, M.Sc., Koon Teo, Ph.D., Denis Xavier, M.D., Patricio L?pez-Jaramillo, Ph.D., Khalid Yusoff, M.B., B.S., Anwar Santoso, Ph.D., Habib Gamra, M.D., Shamim Talukder, M.B., B.S., Courtney Christou, B.Sc.,
doi : 10.1056/NEJMoa2028220
N Engl J Med 2021; 384:216-228
A polypill comprising statins, multiple blood-pressure–lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen, M.D., Ajay Nirula, M.D., Ph.D., Barry Heller, M.D., Robert L. Gottlieb, M.D., Ph.D., Joseph Boscia, M.D., Jason Morris, M.D., Gregory Huhn, M.D., M.P.H.T.M., Jose Cardona, M.D., Bharat Mocherla, M.D., Valentina Stosor, M.D., Imad Shawa, M.D., Andrew C. Adams, Ph.D.,
doi : 10.1056/NEJMoa2029849
N Engl J Med 2021; 384:229-237
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M. Weinreich, M.D., Sumathi Sivapalasingam, M.D., Thomas Norton, M.D., Shazia Ali, Pharm.D., Haitao Gao, Ph.D., Rafia Bhore, Ph.D., Bret J. Musser, Ph.D., Yuhwen Soo, Ph.D., Diana Rofail, Ph.D., Joseph Im, B.S., Christina Perry, M.B.A., Cynthia Pan, B.Pharm.,
doi : 10.1056/NEJMoa2035002
N Engl J Med 2021; 384:238-251
Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and ?-Thalassemia
Haydar Frangoul, M.D., David Altshuler, M.D., Ph.D., M. Domenica Cappellini, M.D., Yi-Shan Chen, Ph.D., Jennifer Domm, M.D., Brenda K. Eustace, Ph.D., Juergen Foell, M.D., Josu de la Fuente, M.D., Ph.D., Stephan Grupp, M.D., Ph.D., Rupert Handgretinger, M.D., Tony W. Ho, M.D., Antonis Kattamis, M.D.,
doi : 10.1056/NEJMoa2031054
N Engl J Med 2021; 384:252-260
Postinfectious Epigenetic Immune Modifications — A Double-Edged Sword
Andrew R. DiNardo, M.D., Mihai G. Netea, M.D., Ph.D., and Daniel M. Musher, M.D.
doi : 10.1056/NEJMra2028358
N Engl J Med 2021; 384:261-270
Pathergy in Neutrophilic Dermatosis
Ji-Hyun Moon, M.B., B.S., and Julie Huynh, B.Biomed.Sci., M.B., B.S.
doi : 10.1056/NEJMicm1901738
N Engl J Med 2021; 384:271
Pelvic Splenosis
Yanpeng Wang, M.D., Ph.D., and Heping Shen, M.D.
doi : 10.1056/NEJMicm2029104
N Engl J Med 2021; 384:e7
Case 2-2021: A 26-Year-Old Pregnant Woman with Ventricular Tachycardia and Shock
Nandita S. Scott, M.D., Sunu S. Thomas, M.D., Doreen DeFaria Yeh, M.D., Andrew S. Fox, M.D., and R. Neal Smith, M.D.
doi : 10.1056/NEJMcpc2027086
N Engl J Med 2021; 384:272-282
Induction of Fetal Hemoglobin by Gene Therapy
Mark C. Walters, M.D.
doi : 10.1056/NEJMe2034338
N Engl J Med 2021; 384:284-285
Treatment by CRISPR-Cas9 Gene Editing — A Proof of Principle
Harry L. Malech, M.D.
doi : 10.1056/NEJMe2034624
N Engl J Med 2021; 384:286-287
Polypills — A Central Strategy for Improving Cardiovascular Health
Mark D. Huffman, M.D., M.P.H., and Anushka Patel, M.B., B.S., Ph.D.
doi : 10.1056/NEJMe2033310
N Engl J Med 2021; 384:288-289
Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
Myron S. Cohen, M.D.
doi : 10.1056/NEJMe2034495
N Engl J Med 2021; 384:289-291
Audio Interview: An International Look at Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Krista Nottage, M.B., B.S., James O’Connell, M.D., Gary Wong, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2101204
N Engl J Med 2021; 384:e19
Renewed Threat of Nuclear Holocaust Requires Physician Activism
doi : 10.1056/NEJMc2033335
N Engl J Med 2021; 384:292
